PL3283110T3 - Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r) - Google Patents
Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)Info
- Publication number
- PL3283110T3 PL3283110T3 PL16780800T PL16780800T PL3283110T3 PL 3283110 T3 PL3283110 T3 PL 3283110T3 PL 16780800 T PL16780800 T PL 16780800T PL 16780800 T PL16780800 T PL 16780800T PL 3283110 T3 PL3283110 T3 PL 3283110T3
- Authority
- PL
- Poland
- Prior art keywords
- receptor
- targeted against
- antibodies targeted
- against interleukin
- interleukin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147824P | 2015-04-15 | 2015-04-15 | |
| PCT/US2016/027676 WO2016168542A1 (en) | 2015-04-15 | 2016-04-15 | Antibodies directed against interleukin 36 receptor (il-36r) |
| EP16780800.5A EP3283110B1 (en) | 2015-04-15 | 2016-04-15 | Antibodies directed against interleukin 36 receptor (il-36r) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3283110T3 true PL3283110T3 (pl) | 2022-06-27 |
Family
ID=57126337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16780800T PL3283110T3 (pl) | 2015-04-15 | 2016-04-15 | Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r) |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10526410B2 (OSRAM) |
| EP (2) | EP4176900A1 (OSRAM) |
| JP (4) | JP6913026B2 (OSRAM) |
| KR (1) | KR102666920B1 (OSRAM) |
| CN (2) | CN115925932A (OSRAM) |
| AU (1) | AU2016248208B2 (OSRAM) |
| CA (1) | CA2982555A1 (OSRAM) |
| DK (1) | DK3283110T3 (OSRAM) |
| ES (1) | ES2914243T3 (OSRAM) |
| MX (2) | MX2017013080A (OSRAM) |
| PL (1) | PL3283110T3 (OSRAM) |
| RU (1) | RU2745898C2 (OSRAM) |
| SG (1) | SG11201708061TA (OSRAM) |
| WO (1) | WO2016168542A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA031948B1 (ru) | 2011-11-16 | 2019-03-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Антитело к il-36r или его антигенсвязывающий фрагмент, выделенный полинуклеотид, клетка-хозяин и способ получения этого антитела или его фрагмента, содержащая их фармацевтическая композиция и применение антитела или его фрагмента и композиции |
| MX2017013080A (es) * | 2015-04-15 | 2018-02-09 | Anaptysbio Inc | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). |
| WO2018183173A1 (en) * | 2017-03-27 | 2018-10-04 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
| EP3400962A1 (en) | 2017-05-09 | 2018-11-14 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | Inhibitors of il-38 for use in treating and/or preventing cancer in a subject |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| CA3090421A1 (en) * | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease |
| IL277215B2 (en) * | 2018-03-14 | 2025-10-01 | Boehringer Ingelheim Int | Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis |
| CN112513091B (zh) * | 2018-07-16 | 2024-08-27 | 瑞泽恩制药公司 | 抗il36r抗体 |
| WO2020018511A1 (en) | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of ditra disease and uses thereof |
| CN110818796B (zh) * | 2018-08-09 | 2022-11-08 | 东莞市朋志生物科技有限公司 | 一种抗人ca153蛋白的重组抗体 |
| AR123405A1 (es) * | 2018-12-21 | 2022-11-30 | 23Andme Inc | Anticuerpos anti-il-36 y métodos de uso de estos |
| TW202037604A (zh) * | 2018-12-27 | 2020-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 治療掌蹠膿疱症之抗il-36r抗體 |
| CN116063505B (zh) | 2019-01-30 | 2024-05-03 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CA3132917A1 (en) * | 2019-03-08 | 2020-09-17 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibody formulations |
| AU2020325315A1 (en) | 2019-08-07 | 2022-03-24 | Aqualung Therapeutics Corp. | Anti-NAMPT antibodies and uses thereof |
| WO2021112196A1 (ja) * | 2019-12-05 | 2021-06-10 | 学校法人東京薬科大学 | 筋組織の減少を抑制するための組成物 |
| AR120913A1 (es) * | 2019-12-27 | 2022-03-30 | Teijin Pharma Ltd | Anticuerpo que inhibe específicamente la señalización de il-36r |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| KR20230038774A (ko) | 2020-07-17 | 2023-03-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 호중성 피부병의 치료를 위한 항-il-36r 항체 |
| AU2021319103A1 (en) * | 2020-07-30 | 2023-02-09 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (IL-36r) therapy for ichthyosis |
| WO2022026829A1 (en) | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity |
| CN112094349B (zh) * | 2020-11-04 | 2021-02-09 | 上海华奥泰生物药业股份有限公司 | 靶向于白介素36r的抗体及其制备方法和应用 |
| WO2022150642A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa |
| WO2022150644A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for acne |
| JP7662804B2 (ja) * | 2021-03-04 | 2025-04-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 汎発性膿疱性乾癬を処置する方法 |
| US20220290239A1 (en) | 2021-03-12 | 2022-09-15 | Boehringer Ingelheim International Gmbh | Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis |
| CN117615788A (zh) * | 2021-05-12 | 2024-02-27 | 安奈普泰斯生物有限公司 | 抗体组合物 |
| WO2023285362A1 (en) | 2021-07-12 | 2023-01-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-36 inhibitors for the treatment of netherton syndrome |
| TW202323293A (zh) * | 2021-10-29 | 2023-06-16 | 新加坡商創響私人有限公司 | 新型抗ｉｌ－３６ｒ抗體 |
| CN115724975A (zh) * | 2022-10-20 | 2023-03-03 | 江苏荃信生物医药股份有限公司 | 抗人白介素36受体单克隆抗体及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| DE69128037T2 (de) | 1990-11-13 | 1998-05-07 | Immunex Corp., Seattle, Wash. | Bifunktionelle wählbare fusionsgene |
| CA2163427A1 (en) | 1993-05-21 | 1994-12-08 | Stephen D. Lupton | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| AU2001233212A1 (en) | 2000-02-02 | 2001-08-14 | Schering Corporation | Mammalian cytokines; receptors; related reagents and methods |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| EP2074139B1 (en) | 2006-09-08 | 2013-10-23 | Amgen, Inc | Il-1 family variants |
| EP2126087A4 (en) | 2007-02-20 | 2010-10-27 | Anaptysbio Inc | METHODS FOR PRODUCING PHARMACOTHEQUES, AND USES THEREOF |
| EP2337799A2 (en) | 2008-08-28 | 2011-06-29 | Wyeth LLC | Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases |
| WO2013016220A1 (en) * | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| EA031948B1 (ru) * | 2011-11-16 | 2019-03-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Антитело к il-36r или его антигенсвязывающий фрагмент, выделенный полинуклеотид, клетка-хозяин и способ получения этого антитела или его фрагмента, содержащая их фармацевтическая композиция и применение антитела или его фрагмента и композиции |
| US9475872B2 (en) * | 2011-12-28 | 2016-10-25 | Immunoqure Ag | Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F |
| JP6162319B2 (ja) | 2013-03-12 | 2017-07-12 | デシミューン セラピューティクス，インコーポレイテッド | ヒト化抗ｎ２抗体 |
| MX2017013080A (es) * | 2015-04-15 | 2018-02-09 | Anaptysbio Inc | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). |
| WO2018183173A1 (en) | 2017-03-27 | 2018-10-04 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
| CA3090421A1 (en) | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease |
| IL277215B2 (en) | 2018-03-14 | 2025-10-01 | Boehringer Ingelheim Int | Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis |
| CN112513091B (zh) | 2018-07-16 | 2024-08-27 | 瑞泽恩制药公司 | 抗il36r抗体 |
| AR123405A1 (es) | 2018-12-21 | 2022-11-30 | 23Andme Inc | Anticuerpos anti-il-36 y métodos de uso de estos |
| TW202037604A (zh) | 2018-12-27 | 2020-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 治療掌蹠膿疱症之抗il-36r抗體 |
| CA3132917A1 (en) | 2019-03-08 | 2020-09-17 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibody formulations |
| US20220233710A1 (en) | 2019-05-20 | 2022-07-28 | Nantong Yichen Biopharma. Co. Ltd. | Bispecific molecule and preparation and use thereof |
-
2016
- 2016-04-15 MX MX2017013080A patent/MX2017013080A/es unknown
- 2016-04-15 EP EP22162381.2A patent/EP4176900A1/en active Pending
- 2016-04-15 WO PCT/US2016/027676 patent/WO2016168542A1/en not_active Ceased
- 2016-04-15 EP EP16780800.5A patent/EP3283110B1/en active Active
- 2016-04-15 US US15/567,045 patent/US10526410B2/en active Active
- 2016-04-15 DK DK16780800.5T patent/DK3283110T3/da active
- 2016-04-15 ES ES16780800T patent/ES2914243T3/es active Active
- 2016-04-15 KR KR1020177032985A patent/KR102666920B1/ko active Active
- 2016-04-15 JP JP2017553885A patent/JP6913026B2/ja active Active
- 2016-04-15 AU AU2016248208A patent/AU2016248208B2/en active Active
- 2016-04-15 PL PL16780800T patent/PL3283110T3/pl unknown
- 2016-04-15 CN CN202210803364.8A patent/CN115925932A/zh active Pending
- 2016-04-15 CN CN201680034793.6A patent/CN107847590B/zh active Active
- 2016-04-15 SG SG11201708061TA patent/SG11201708061TA/en unknown
- 2016-04-15 RU RU2017139481A patent/RU2745898C2/ru active
- 2016-04-15 CA CA2982555A patent/CA2982555A1/en active Pending
-
2017
- 2017-10-11 MX MX2023001791A patent/MX2023001791A/es unknown
-
2019
- 2019-11-18 US US16/686,373 patent/US11130814B2/en active Active
-
2021
- 2021-04-15 JP JP2021069306A patent/JP7212098B2/ja active Active
- 2021-08-26 US US17/412,737 patent/US12391761B2/en active Active
-
2023
- 2023-01-12 JP JP2023003385A patent/JP7721585B2/ja active Active
-
2025
- 2025-07-30 JP JP2025127775A patent/JP2025163120A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3283110T3 (pl) | Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r) | |
| IL272227A (en) | Anti-tigit antibodies | |
| IL272274A (en) | B7-h4 antibodies and methods of use thereof | |
| IL269002A (en) | Antibodies against pd-l1 | |
| IL263834A (en) | Anti-pd-l1 antibodies | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| PT3606954T (pt) | Anticorpos anti-lag3 | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| IL257798A (en) | Anti-lag-3 antibodies | |
| CL2018000281A1 (es) | Anticuerpos monoclonales contra bcma | |
| SI3354729T1 (sl) | Protitelesa anti-garp | |
| HUE047929T2 (hu) | Kiméra antigén receptor | |
| DK3368060T3 (da) | Glugacon-receptor-agonister | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| EP3596108A4 (en) | TARGETED IMMUNOTOLERANCE | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| EP3684806A4 (en) | NEW ANTI-CD3EPSILON ANTIBODIES | |
| IL256099A (en) | Antibody | |
| EP3720871A4 (en) | TARGETED IMMUNOTOLERANCE | |
| EP3596126A4 (en) | NEW ANTI-TRKB ANTIBODIES | |
| DK3484921T3 (da) | Anti-IL-22R antistoffer |